Member Info for Matml74

They are doing a different trial.

Pegylated Interferon - a2b With SARSCoV- 2 (COVID-19) Recruiting Phase 2 40 Cadila Healthcare Limited NCT04480138

If there was a rumour in the city about US SNG001 order this share price would be blowing up.

He will start saying it once Activ-2 starts. We all know its starting. Only been 8 days since the RNS.

Org, Parexel do that.

https://www.parexel.com/solutions/clinical-development-services/clinical-data-management

Mike, I don't think we will get one for P3 but should once Activ-2 is underway.

" Our data show that therapeutic induction of ISGs in immune cells might be a treatment option in early disease. So far, data on interferon-based therapy in COVID-19 is inconclusive, but a study utilizing inhaled nebulized interferon beta-1 in non-severe COVID- 19 showed promising results86, 87. Intriguingly, retrospective analysis of a cohort trial with IFN-alpha2 indicated that early interferon treatment might be beneficial regarding clinical outcomes, with harmful effects late in the disease88. However, side-effects and the abovementioned autoantibodies as well as signaling mutations in patients susceptible to SARS-CoV-2 might limit the use of interferon-alpha or beta15, 16, 89.
In summary, our data provide important implications for therapy and disease course prediction in SARS-CoV-2 infection. By measuring ISG responses in peripheral immune
bioRxiv preprint doi: https://doi.org/10.1101/2021.02.03.429351; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
cells, patients could potentially be segregated in ARDS high/low risk cohorts. Treatment with interferons early in disease might be able to tip the inflammatory response towards local pathogen control, possibly preventing severe COVID-19 and its potentially fatal consequences."

When will regulatory agencies get the message.....

"In conclusion, our data demonstrate a protective ISG phenotype in patients with successful containment of SARS-CoV-2 infection without progression to COVID-19. This early protective interferon response might be exploited as a therapeutic approach and for disease course prediction."

https://www.biorxiv.org/content/10.1101/2021.02.03.429351v1.full.pdf

Andy, good to have you here posting. We are in for an exciting few months with this share. Enjoy the ride. GL

What day is the SD interview?

Didn’t check the rns’s last week then?

I stand corrected. 2 minutes!

16:35 177.00 50,985 181.00
16:35 177.00 50,985 181.00
16:35 176.00 51,457 181.00
16:35 177.00 50,985 181.00
16:35 177.00 50,985 181.00
16:35 177.00 50,985 181.00
16:35 176.00 51,528 181.00
16:35 176.00 51,316 181.00
16:35 177.00 50,985 181.00
16:35 177.00 50,985 181.00
16:35 176.00 51,528 181.00
16:35 176.00 52,073 181.00
16:35 176.00 51,529 181.00
16:35 177.00 50,985 181.00
16:35 177.00 50,985 181.00
16:35 177.00 50,083 181.00
16:35 177.00 50,663 181.00
16:35 177.00 50,985 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,643 181.00
16:35 176.00 53,477 181.00
16:34 175.00 58,751 181.00
16:34 175.00 58,171 181.00
16:34 175.00 55,164 181.00
16:34 175.00 54,436 181.00
16:34 175.00 55,017 181.00
16:34 175.00 55,490 181.00
16:34 175.00 55,702 181.00
16:34 175.00 54,743 181.00
16:34 175.00 56,860 181.00
16:34 176.00 53,643 181.00
16:34 175.00 54,223 181.00
16:34 175.00 54,804 181.00
16:34 175.00 54,223 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 175.00 56,096 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 176.00 51,457 181.00
16:34 177.00 50,985 181.00
16:34 176.00 51,410 181.00
16:34 176.00 52,457 181.00
16:34 176.00 52,227 181.00
16:34 176.00 52,015 181.00
16:34 176.00 51,589 181.00
16:34 177.00 50,985 181.00
16:34 177.00 50,985 181.00
16:34 177.00 50,985 181.00
16:34 177.00 50,985 181.00
16:34 177.00 50,985 181.00
16:34 176.00 53,147 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,020 181.00
16:34 176.00 53,643 181.00
16:34 176.00 53,643 181.00
16:34 177.00 50,881 181.00

Sileng, there were 66 x 50,000 shares bought in 4 mins! It was not normal!

ST, I don't know either way. Local planing committees are made up of locally elected councillors and they all have their political leanings and are easily influenced by local lobby groups. I have experienced this on a number of planning applications I have been involved in. I think this is the better route for the planning to get passed, however having read the letter posted below it is not certain yet that this application won't go back to the local authority.

Kenneth, Contact Synairgen as first point of call. There are details on their website regarding MAP and a contact number.

There was a risk here that the planning committee could have rejected the council planners recommendation for approval. Have seen it many times on residential planning applications. This is a good result. I find it highly unlikely that the Welsh government won't now approve this application.

Jurado, Yes that is how it works. Should be an rns today at some point. Tempted to have a little trade on this one.

I'm with you Ray.

This is great news but is all in the context of a society that is completely locked down. If transmission is not dropping now it never will!

So basically the UK NIHR urgent status means SFA unless your part of recovery trial.

HC, it should boost the SP in the AM particularly if these shares haven’t filled the whole order. The other thing is 4 million shares would have wiped off a chunk of stock from the mm’s books so if the need more stock then price should move higher.